LMT503 First-in-human SAD, MAD, and FE Study
Phase 1
Not yet recruiting
- Conditions
- Colitis, UlcerativeCrohn DiseaseInflammatory Bowel Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-12-21
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Lmito Therapeutics Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT05659953
- Locations
- 🇳🇱
ICON plc Company - Early Development Services, Groningen, NZ, Netherlands
© Copyright 2025. All Rights Reserved by MedPath